logo
Our Place founder warns supermarket dupes will 'cause businesses to fail'

Our Place founder warns supermarket dupes will 'cause businesses to fail'

Yahoo14 hours ago
Supermarkets launching copycat versions of labels will 'destroy' innovation and cause small businesses to fail, the co-founder of a kitchenware brand backed by Gwyneth Paltrow and Jay-Z has warned.
Our Place co-founder and co-chief executive Shiza Shahid said the brand was growing rapidly in the UK despite dupes appearing on the market.
Ms Shahid launched the Los Angeles-based business with her husband in 2019, with Will Smith's Dreamers VC, Jay-Z's Marcy Venture Partners, and Gwyneth Paltrow among its early investors.
It specialises in kitchenware including pans designed to be non-toxic and non-stick, and collections created in complementary colours and aesthetics.
Widely-shared posts on social media, especially Instagram, have helped drive popularity of the brand in recent years – including a collaboration with actress and singer Selena Gomez.
Similar versions of bestselling products – namely the 'Always Pan' which currently sells for £125 – have recently launched in supermarkets including Aldi and Marks & Spencer with a lower price tag.
Ms Shahid told the PA news agency: 'Unfortunately I think it is incredibly harmful.
'When we started Our Place, my partner and I bootstrapped our savings and worked on the design for two years before we ever sold a single unit.
'And when multi-million dollar corporations come and they knock it off, with no regard for innovation, IP, small business, they are causing tremendous harm and it will cause a lot of businesses to fail, and it will destroy innovation.'
She said such companies are 'very skilled in the art of duplicity' which makes it difficult and costly for smaller brands to legally challenge.
But the businesswoman told PA that they were 'not able to guarantee that same level of detail and quality' with replica products.
'So we trust that, while not every consumer will see the difference, many will and many do,' she said, adding that shoppers often want to 'support brands that they believe in'.
A spokesman for Aldi said: 'For over 35 years we have championed customers by offering high quality exclusive products at the lowest possible prices.
'We go to great lengths to ensure that all our exclusive brand products are compliant with strict copyright laws and regulations.'
M&S has been contacted for comment.
Ms Shahid, who also co-founded the Malala Fund with Nobel Prize winner and campaigner Malala Yousafzai, said Our Place products are typically viewed as an 'accessible luxury'.
'Despite some of the cost-of-living challenges, people are investing in the home and kitchen,' she told PA.
'The first thing you do is maybe you go out a little bit less, but then you still want the joy and the nourishment and the connection, and home cooking is a really great way to do that.
'It feels like an everyday luxury… people are choosing products that will last, that will bring joy, and that will actually help them save money over time.'
Sales across the brand spiked by 92% over the first quarter of 2025 compared with the same period last year, and it has built more than a million active customers.
It is also set to launch a shop-in-shop space within London department store Selfridges amid efforts to expand into retailers and take on established competitors such as Le Creuset.
Ms Shahid said Our Place has 'a lot of younger consumers but we also have a lot of men and women in their 60s', while many of its products – including the countertop 'wonder oven' – appeal to single-person households and small families.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Stays Positive on Visa (V), Keeps Buy Rating
Citi Stays Positive on Visa (V), Keeps Buy Rating

Yahoo

time35 minutes ago

  • Yahoo

Citi Stays Positive on Visa (V), Keeps Buy Rating

Visa Inc. (NYSE:V) is one of the 11 Best Fintech Stocks to Buy Right Now. On May 21, Citi maintained its 'Buy' rating on Visa Inc. (NYSE:V) and maintained a $396 price target. This decision came after meetings with Visa Inc. (NYSE:V) executives in London that were well-attended. Analysts feel more positive about the company's future prospects. A close-up of a modern payments terminal with a pile of credit cards on the side. The meetings included discussion about new trends that could renew interest in the fintech sector. These trends include agent-based commerce and stablecoins. This reinforces confidence in Visa Inc.'s (NYSE:V) potential for growth. Citi analysts believe that the wide range of available opportunities, along with the company's strong position, make Visa Inc. (NYSE:V) a top financial technology investment idea. Visa Inc. (NYSE:V) is an American multinational financial technology and digital payments company that offers a variety of payment products and payment processing to facilitate electronic payments in over 200 countries and territories. While we acknowledge the potential of V as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None.

Terry Smith Blasts Novo, Coloplast in Danish Life Science Rebuke
Terry Smith Blasts Novo, Coloplast in Danish Life Science Rebuke

Yahoo

time43 minutes ago

  • Yahoo

Terry Smith Blasts Novo, Coloplast in Danish Life Science Rebuke

(Bloomberg) -- Terry Smith slammed two of Denmark's largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they weighed on the equity fund run by the man often dubbed 'Britain's Warren Buffett.' Foreign Buyers Swoop on Cape Town Homes, Pricing Out Locals Trump's Gilded Design Style May Be Gaudy. But Don't Call it 'Rococo.' Are Tourists Ruining Europe? How Locals Are Pushing Back Massachusetts to Follow NYC in Making Landlords Pay Broker Fees In California, Pro-Housing 'Abundance' Fans Rewrite an Environmental Landmark Novo's 'ability to snatch defeat from the jaws of victory in respect of its leadership in weight loss drugs continues to be remarkable,' Smith wrote in his semiannual letter to shareholders. The fund manager also said he is waiting with 'increasingly thin patience' for Novo and medical device manufacturer Coloplast to announce replacements for their ousted chief executives. Smith's Fundsmith Equity Fund slipped 1.9% in the first six months of the year, a drop he said was 'almost all' caused by the holding in Novo. After its Ozempic diabetes treatment and sister drug Wegovy sparked the global obesity craze that made it Europe's most valuable company, Novo has recently struggled to convince investors it has the pipeline to fend off scores of emerging rivals. Eli Lilly & Co. has been gaining the upper hand in the US, where Novo has also struggled to prevent the proliferation of cheaper copycat weight-loss shots. 'Its inability to deal with the US legal and regulatory system's approach to its success would be interesting to observe from a safe distance,' Smith said. Novo is a top-10 holding in the Fundsmith portfolio, according to its website. Novo declined to comment on Smith's letter. Shares of the drugmaker are down almost 30% so far this year. Meanwhile Coloplast's shares have slumped 23% this year as it struggled to generate sufficient growth from acquisitions, including the $1.3 billion takeover of Kerecis hf, an Icelandic maker of fish-skin dressings to treat human wounds. 'Coloplast was a company whose revenue growth rate was metronomic,' Smith wrote. 'Probably not coincidentally, following two major acquisitions, it has encountered a series of operational failures.' Coloplast didn't immediately respond to a request for comment. Both Novo and Coloplast are controlled by foundations, a model favored by some Danish companies that Smith said he has seen as a strength. Now, he is growing frustrated with the pace of change as they prepare for new leadership. Novo's CEO Lars Fruergaard Jorgensen was ousted in May in a move that shocked investors. Kristian Villumsen, Coloplast's CEO, was pushed out in the same month, with the chairman saying the company failed to deliver. --With assistance from Leonard Kehnscherper. For Brazil's Criminals, Coffee Beans Are the Target SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too Sperm Freezing Is a New Hot Market for Startups Pistachios Are Everywhere Right Now, Not Just in Dubai Chocolate China's Homegrown Jewelry Superstar ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store